Global Lung Cancer Academy

Sharing Best Practices to Optimize Patient Care in Latin America and Canada

Overview

In recent years, progress in screening of high-risk populations, identification of actionable molecular targets, and immunotherapy have rapidly transformed the treatment paradigm for patients with lung cancer. Aptitude Health developed the Global Lung Cancer Academy to help physicians bridge the gap between innovation and implementation for patient care.

Date and Location

October 21 and 24, 2022; Virtual Meeting

Meeting Content

View the slides and watch the video of Day 1

View the slides and watch the video of Day 2

Co-chairs

Corey Langer

Corey J. Langer, MD, FACP

University of Pennsylvania Perelman School of Medicine, USA

Carlos Barrios

Carlos H. Barrios, MD

Oncology Research Center at Hospital São Lucas, PUCRS, Brazil

Faculty

Narjust Florez

Narjust Florez (Duma), MD

Dana-Farber Cancer Institute/Harvard Cancer Center

Barbara Melosky

Barbara Melosky, MD, FRCP

University of British Columbia Vancouver, Canada

Edgardo Santos

Edgardo S. Santos, MD

GenesisCare Hematology/Oncology, USA

Anne Tsao

Anne S. Tsao, MD, MBA

University of Texas MD Anderson Cancer Center, USA

Ignacio Wistuba

Ignacio I. Wistuba, MD

MD Anderson Cancer Center, USA

William William

William William, MD

BP, A Beneficência Portuguesa de São Paulo, Brazil

Agenda

This 2-day interactive virtual meeting with global experts will focus on the management of patients with lung cancer in Latin America and Canada.

Day 1: Follow presentations and engage with the faculty in case-based panel discussions on optimal treatment and patient access, and regional challenges across Latin America and Canada

Day 2: Join presentations on region-specific management and treatment strategies for early-stage and metastatic NSCLC in Latin America and attend patient case-based panel discussions exemplifying these strategies

Day 1 – Plenary Sessions
Friday, October 21, 2022 from 4.00 PM – 8.00 PM EDT (GMT –4)

Time Topic Speaker
4.00 PM
4.10 PM
Welcome and Meeting Overview Corey Langer
4.10 PM
4.40 PM
Recent Developments in NSCLC – What Is New in Research and Management?
• Overview of recently presented data in NSCLC
Corey Langer
4.40 PM
5.00 PM
Biomarker and Mutational Testing for NSCLC – What, Where, and When?
• NSCLC heterogeneity, overview of current and emerging biomarkers and comutations, and best practices and guidelines for testing at diagnosis and during treatment of NSCLC
Ignacio Wistuba
5.00 PM
5.20 PM
Neoadjuvant Therapy for NSCLC – Is It Ready for Prime Time?
• Current state of neoadjuvant therapy in resectable vs unresectable NSCLC
Anne Tsao
5.20 PM
5.50 PM
Debate: Adjuvant or Neoadjuvant Therapy for NSCLC?
• Neoadjuvant therapy
• Adjuvant therapy
• Discussion and voting
Moderator: Corey Langer
Anne Tsao
Narjust Florez
All faculty
5.50 PM
6.00 PM
Break  
6.00 PM
6.20 PM
Locally Advanced, Unresectable NSCLC – What Are the Options?
• Current standard practices and ongoing studies
Edgardo S. Santos
6.20 PM
6.40 PM
Targeted Therapies for NSCLC
• Summary of targeted therapies for different NSCLC genotypes
Barbara Melosky
6.40 PM
7.00 PM
Immunotherapy Approaches for Advanced NSCLC
• Predictive biomarkers, monotherapy vs combination therapy strategies, mechanism of resistance, and rechallenge
Edgardo S. Santos
7.00 PM
7.20 PM
De Novo – or at Relapse – Oligometastatic NSCLC: Management of Local and Systemic Disease
• Work-up of first recurrence vs de novo oligometastatic NSCLC including sites of involvement (isolated vs systemic recurrence)
Narjust Florez
7.20 PM
7.50 PM
Tumor Board Discussion
• Case 1: Resectable Stage III NSCLC
• Case 2: Resectable Stage III NSCLC
• Discussion and Q&A
Moderator: Corey Langer
Vinícius Lorandi
Barbara Melosky
All faculty
7.50 PM
8.00 PM
Session Close Corey Langer

Day 2: Virtual Plenary Session – Limited Access Sessions
Monday, 24 October 2022 from 4.00 PM – 7.00 PM EDT (GMT –4)

Time Topic Speaker
4.00 PM
4.10 PM
Session Open Corey Langer and Carlos Barrios
4.10 PM
4.40 PM
Interactive Discussion: Regional Challenges in NSCLC Management
• Interactive discussion and Q&A (15 min)
Moderator: Carlos Barrios All faculty
4.40 PM
5.00 PM
Current Diagnostic Options and Initial Management of Early-Stage NSCLC in Latin America
• Overview of currently available diagnostic methods and treatment options for early-stage NSCLC (resectable vs unresectable)
William William
5.00 PM
5.20 PM
Current Treatment Options for Metastatic NSCLC in Latin America
• Overview of currently available treatment options for metastatic NSCLC
Carlos Barrios
5.20 PM
5.50 PM
Tumor Board Discussion
• Case 1: EGFR+ metastatic NSCLC
• Case 2: HER2+ metastatic NSCLC
• Discussion and Q&A
Moderator: Carlos Barrios
Caio Abner Leite
Alvaro Guimaraes Paula
All faculty
5.50 PM
6.00 PM
Break  
6.00 PM
6.20 PM
Monitoring and Managing Immunotherapy-Related AEs
• Optimal monitoring and managing of the most common AEs associated with immunotherapy
Edgardo S. Santos
6.20 PM
6.50 PM
Tumor Board Discussion
• Patient case (10 min)
• Discussion and Q&A (20 min)
Moderator: Corey Langer
Barbara Melosky
6.50 PM
7.00 PM
Session Close Carlos Barrios